NCT04739111 - An Exploratory Clinical Study of LDP Combined With CDP1 in Patients With Advanced Malignant Tumor | Biotech Hunter

Enrollment

130

Participants

Timeline

Start Date

January 29, 2021

Primary Completion Date

February 28, 2023

Study Completion Date

February 29, 2024

Conditions

Advanced Malignant Tumor

Interventions

DRUG

Human Anti-PD-L1 Monoclonal Antibody Injection (LDP) Combined with Recombinant Anti-EGFR Human Mouse Chimeric Monoclonal Antibody Injection (CDP1)

In the dose-escalation phase, CDP1 400 mg/ m2 will be given in the first week, then 250 mg/m2 will be given evert week. LDP will be given every two weeks with dose climbing of 5 mg/kg, 10 mg/kg, 20 mg/kg. Dose in the dose-expansion phase according to the assesment in the dose-escalation phase.

Trial Locations (1)

Unknown

RECRUITING

Dragonboat Biopharmaceutical,Co.,Ltd, Shanghai